Moderna, Inc. (MRNA)
MRNA Stock Price Chart
Explore Moderna, Inc. interactive price chart. Choose custom timeframes to analyze MRNA price movements and trends.
MRNA Company Profile
Discover essential business fundamentals and corporate details for Moderna, Inc. (MRNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Dec 2018
Employees
5.80k
Website
https://www.modernatx.comCEO
Stéphane Bancel
Description
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Financial Timeline
Browse a chronological timeline of Moderna, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 31 Jul 2026
EPS estimate is -$2.04, while revenue estimate is $103.10m.
Earnings released on 1 May 2026
EPS came in at -$3.40 surpassing the estimated -$4.45 by +23.60%, while revenue for the quarter reached $389.00m , beating expectations by +64.58%.
Earnings released on 13 Feb 2026
EPS came in at -$2.11 surpassing the estimated -$2.54 by +16.93%, while revenue for the quarter reached $678.00m , beating expectations by +6.75%.
Earnings released on 6 Nov 2025
EPS came in at -$0.51 surpassing the estimated -$1.87 by +72.73%, while revenue for the quarter reached $1.02bn , beating expectations by +10.33%.
Earnings released on 1 Aug 2025
EPS came in at -$2.13 surpassing the estimated -$2.99 by +28.76%, while revenue for the quarter reached $142.00m , missing expectations by -84.10%.
Earnings released on 1 May 2025
EPS came in at -$2.52 surpassing the estimated -$2.92 by +13.70%, while revenue for the quarter reached $107.00m , missing expectations by -8.35%.
Earnings released on 14 Feb 2025
EPS came in at -$2.50 surpassing the estimated -$2.68 by +6.72%, while revenue for the quarter reached $956.00m , beating expectations by +1.40%.
Earnings released on 7 Nov 2024
EPS came in at $0.03 surpassing the estimated -$1.91 by +101.57%, while revenue for the quarter reached $1.86bn , beating expectations by +48.39%.
Earnings released on 1 Aug 2024
EPS came in at -$3.33 surpassing the estimated -$3.35 by +0.60%, while revenue for the quarter reached $241.00m , beating expectations by +87.68%.
Earnings released on 2 May 2024
EPS came in at -$3.07 surpassing the estimated -$3.56 by +13.76%, while revenue for the quarter reached $167.00m , beating expectations by +79.07%.
Earnings released on 22 Feb 2024
EPS came in at $0.55 surpassing the estimated -$0.97 by +156.70%, while revenue for the quarter reached $2.81bn , beating expectations by +12.02%.
Earnings released on 2 Nov 2023
EPS came in at -$1.39 surpassing the estimated -$2.01 by +30.85%, while revenue for the quarter reached $1.83bn , beating expectations by +38.27%.
Earnings released on 3 Aug 2023
EPS came in at -$3.62 surpassing the estimated -$3.84 by +5.73%, while revenue for the quarter reached $344.00m , beating expectations by +7.62%.
Earnings released on 4 May 2023
EPS came in at $0.19 surpassing the estimated -$1.77 by +110.73%, while revenue for the quarter reached $1.84bn , beating expectations by +56.01%.
Earnings released on 23 Feb 2023
EPS came in at $3.61 falling short of the estimated $4.68 by -22.86%, while revenue for the quarter reached $5.08bn , beating expectations by +1.33%.
Earnings released on 3 Nov 2022
EPS came in at $2.53 falling short of the estimated $3.29 by -23.10%, while revenue for the quarter reached $3.22bn , missing expectations by -8.69%.
Earnings released on 3 Aug 2022
EPS came in at $5.24 surpassing the estimated $4.55 by +15.16%, while revenue for the quarter reached $4.57bn , beating expectations by +11.45%.
Earnings released on 4 May 2022
EPS came in at $8.58 surpassing the estimated $5.21 by +64.68%, while revenue for the quarter reached $5.94bn , beating expectations by +41.30%.
Earnings released on 24 Feb 2022
EPS came in at $11.29 surpassing the estimated $9.90 by +14.04%, while revenue for the quarter reached $6.95bn , beating expectations by +2.23%.
Earnings released on 4 Nov 2021
EPS came in at $7.70 falling short of the estimated $9.05 by -14.92%, while revenue for the quarter reached $4.83bn , missing expectations by -25.09%.
Earnings released on 5 Aug 2021
EPS came in at $6.46 surpassing the estimated $5.96 by +8.39%, while revenue for the quarter reached $4.22bn , beating expectations by +0.18%.
MRNA Stock Performance
Access detailed MRNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
